IKBIP

IKBIP (IKIP) is a stress-responsive intracellular protein that functions both as a negative regulator of canonical NF-κB signaling and as a context-dependent driver of cancer cell proliferation and invasion (PMID:31826938, PMID:36244542). It was first identified as a p53 target gene whose induction by X-irradiation promotes apoptosis in endothelial cells, sharing a bidirectional promoter with APAF1 (PMID:15389287). Mechanistically, IKIP binds IKKα/β and blocks their association with NEMO, suppressing IKKα/β phosphorylation and downstream IκB/p65 phosphorylation; loss of IKIP prolongs IKK activation and sensitizes mice to LPS-induced septic shock and DSS-induced colitis (PMID:31826938). This inhibitory function is itself relieved by GULP1, which binds IKIP to restore IKKβ-dependent NF-κB activation and downstream OPA1-linked mitochondrial and fatty-acid metabolic recovery in diabetic cardiomyopathy (PMID:42015218). In proliferating tumor cells, IKBIP supports cell cycle progression and invasion through several effectors: it binds CDK4 and protects it from ubiquitin-mediated degradation to sustain Cyclin D1/CDK4-dependent G1/S transit (PMID:36244542), activates PI3K/AKT signaling in esophageal squamous carcinoma (PMID:38914958), drives the Wnt/β-catenin/EMT program in glioma downstream of SP1-mediated transcriptional upregulation (PMID:42004064), and suppresses migration via downregulation of THBS1/FAK signaling (PMID:38948026).

1. 2004 Medium

   Established IKBIP as a genuine stress-response gene by linking its expression to p53 and its function to apoptosis, situating it in the DNA-damage response.

   Evidence Reporter/transfection and X-irradiation assays in endothelial cells plus bidirectional promoter analysis with APAF1

   PMID:15389287

   Open questions at the time

   • No molecular partner or biochemical activity identified
   • Mechanism connecting IKIP to the apoptotic machinery not defined
   • Single cell type tested
2. 2019 High

   Defined IKBIP's core molecular mechanism as a brake on canonical NF-κB signaling, answering how it acts biochemically and demonstrating physiological relevance in inflammation.

   Evidence Reciprocal Co-IP of IKIP with IKKα/β and disruption of IKK–NEMO, knockout macrophages and mice in septic shock and colitis models

   PMID:31826938

   Open questions at the time

   • Binding interface/domain on IKK not mapped
   • Relationship between NF-κB inhibition and earlier apoptotic role unresolved
   • Upstream regulators of IKIP not identified here
3. 2022 Medium

   Revealed a pro-proliferative function distinct from NF-κB inhibition by showing IKBIP stabilizes CDK4, explaining how it sustains cell cycle progression in cancer.

   Evidence Co-IP of IKBIP with CDK4, ubiquitination assay, knockdown cell cycle analysis, and xenograft model in GBM

   PMID:36244542

   Open questions at the time

   • E3 ligase that IKBIP antagonizes not identified
   • Reconciliation of pro-tumor role with apoptotic/p53 role unclear
   • Whether CDK4 stabilization depends on NF-κB activity untested
4. 2024 Medium

   Extended IKBIP's tumor functions to motility control via THBS1/FAK and to a separate PI3K/AKT-dependent proliferation axis in esophageal carcinoma, showing pathway-specific and tissue-specific outputs.

   Evidence Knockdown/overexpression with migration/invasion assays and transcriptomics (GBM, THBS1/FAK) and LY-294002 epistasis with xenografts (ESCC, AKT)

   PMID:38914958 PMID:38948026

   Open questions at the time

   • Direct molecular link between IKBIP and THBS1 transcription or AKT activation not established
   • Opposing effects on growth versus invasion not mechanistically reconciled
   • Whether these axes intersect with NF-κB unknown
5. 2026 Medium

   Placed IKBIP within regulatory circuits by identifying both an upstream activator (SP1) driving a Wnt/β-catenin/EMT program in glioma and a counter-regulator (GULP1) that relieves its NF-κB inhibition with metabolic consequences.

   Evidence SP1–promoter binding plus KD/OE Wnt/EMT readouts (glioma); GULP1–IKIP Co-IP with cardiac KO/OE mice and mitochondrial/metabolic assays (diabetic cardiomyopathy)

   PMID:42004064 PMID:42015218

   Open questions at the time

   • How GULP1 binding sterically relieves IKK inhibition not defined
   • Connection between Wnt/EMT activation and the established IKK-binding function unclear
   • Whether SP1 and GULP1 regulation co-occur in the same tissues untested

• How a single protein integrates its NF-κB-inhibitory, p53/apoptotic, and pro-proliferative (CDK4/AKT/Wnt) activities into a coherent context-dependent program remains unresolved.
• No structural model or domain map for IKBIP
• Determinants of tumor-suppressive versus oncogenic output unknown
• Whether the IKK-binding and CDK4-binding functions are mutually exclusive untested